Purification of Rift Valley Fever Virus-Like Particles for Structural Analyses by Hannula, Liina
Liina Hannula 
UNIVERSITY OF HELSINKI | MASTER'S PROGRAMME IN MICROBIOLOGY AND 
MICROBIAL BIOTECHNOLOGY 
Purification of Rift Valley Fever 
Virus-Like Particles for Structural 
Analyses 
MASTER’S THESIS 
 
 
 
 
 
 
 
 
 
1 
 
 
Tiedekunta – Fakultet – Faculty 
  
Faculty of Acriculture and Forestry ¤ 
And 
Faculty of Biological and Environmental Sciences 
¤coordinating faculty 
Koulutusohjelma – Utbildningsprogram – Degree Programme 
 
Master's Programme in Microbiology and Microbial 
Biotechnology 
Tekijä – Författare – Author 
 Liina Hannula 
Työn nimi – Arbetets titel – Title 
 Purification of Rift Valley Fever Virus-Like Particles for Structural Analyses 
Oppiaine/Opintosuunta – Läroämne/Studieinriktning – Subject/Study track 
Virology 
Työn laji – Arbetets art – Level 
 Master’s thesis 
Aika – Datum – Month and year 
 5/2020 
Sivumäärä – Sidoantal – Number of pages 
 35 
Tiivistelmä – Referat – Abstract 
 
Rift Valley fever virus (RVFV) is a mosquito-borne virus of the order Bunyavirales with 
a tripartite (-)ssRNA genome. It infects humans and cattle, causing a febrile disease 
with symptoms ranging from mild to severe. Safe and efficient human vaccines have 
not yet been developed, which underlines the importance of gaining a clear 
understanding of the viral antigenic surface.  
 
One significant challenge for RVFV research is posed by the costly and time-
consuming biosafety precautions warranted by the pathogenicity of the virus. The 
surface of RVFV, formed by the two viral envelope glycoproteins Gn and Gc, could 
also be studied with a non-pathogenic model, such as a virus-like particle (VLP). A VLP 
is a macromolecular complex that resembles the virus, especially with respect to its 
outer structure, but lacks the viral genome.  
 
In this work, RVFV VLPs were produced by transient transfection of mammalian cells 
with genes encoding RVFV glycoproteins Gn and Gc . The objective was to design an 
optimized production and purification pipeline for RVFV VLPs to elucidate their 
structure by cryo-electron microscopy. To optimize the VLP production and purification, 
the effect of sample harvest times and DNA-to-cell ratios of transfection on RVFV 
glycoprotein expression was examined. Several methods were tested for VLP sample 
concentration and purification. VLPs were successfully detected in the purified samples 
by immuno-electron microscopy. 
 
Despite some challenges related to sample purity and scarcity of VLPs in samples, 
which prevented analyses by cryo-electron microscopy, the expression system 
described in this thesis has great potential to streamline RVFV VLP sample preparation 
for electron microscopy and to accelerate vital research into the structural properties of 
this emerging pathogen. 
 
Avainsanat – Nyckelord – Keywords 
 Rift Valley Fever Virus, virus-like particle, Bunyavirales, structural biology, biocomplex purification 
Ohjaaja tai ohjaajat – Handledare – Supervisor or supervisors 
Juha Huiskonen and Elina Roine 
Säilytyspaikka – Förvaringsställe – Where deposited 
HELDA - Helsingin yliopiston digitaalinen arkisto / HELDA - Helsingfors universitets digitala publikationsarkiv /HELDA - Digital 
Repository of the University of Helsinki 
  
Muita tietoja – Övriga uppgifter – Additional information 
 
2 
 
 
Tiedekunta – Fakultet – Faculty 
  
Maa- ja metsätaloustieteellinen tiedekunta ¤ 
Ja 
Bio- ja ympäristötieteellinen tiedekunta 
¤koordinoiva tiedekunta 
Koulutusohjelma – Utbildningsprogram – Degree Programme 
 
Mikrobiologian ja mikrobibiotekniikan maisteriohjelma 
Tekijä – Författare – Author 
 Liina Hannula 
Työn nimi – Arbetets titel – Title 
 Rift Valley Fever -viruksen kaltaisten partikkelien puhdistus rakenteellisia analyysejä varten 
Oppiaine/Opintosuunta – Läroämne/Studieinriktning – Subject/Study track 
Virologia 
Työn laji – Arbetets art – Level 
 Maisterintutkielma 
Aika – Datum – Month and year 
 5/2020 
Sivumäärä – Sidoantal – Number of pages 
 35 
Tiivistelmä – Referat – Abstract 
 
Rift Valley Fever -virus (RVFV) on hyttyslevitteinen (-)ssRNA-virus (lahko 
Bunyavirales), jonka genomi koostuu kolmesta RNA-segmentistä. RVFV aiheuttaa 
ihmisissä ja karjaeläimissä vakavuudeltaan vaihtelevaa kuumetautia. Turvallisia ja 
tehokkaita ihmisrokotteita ei ole vielä kehitetty, mikä korostaa viruksen ja isännän 
vuorovaikutuksen sekä viruspartikkelin immunogeenisen pinnan tuntemisen tärkeyttä. 
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tuottomenetelmillä on kuitenkin potentiaalia yksinkertaistaa VLP-näytteiden tuottoa 
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2 ABBREVIATIONS 
Cryo-EM = cryo-electron microscopy / electron cryo-microscopy 
CsCl = cesium chloride 
DMEM = Dulbecco’s modified Eagle’s medium 
EM = electron microscopy 
EV = extracellular vesicle 
kDa = kilodalton 
MWCO = molecular weight cutoff 
NMCO = nominal molecular weight cutoff 
PEG = polyethylene glycol 
PEI = polyethyleneimine 
PFA = paraformaldehyde 
RVFV = Rift Valley fever virus 
TEM = transmission electron microscopy 
VLP = virus-like particle 
Å = angstrom 
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3 INTRODUCTION 
Rift Valley fever virus (RVFV) is the causative agent of a mosquito-borne zoonosis that 
affects humans and livestock. The symptoms range from mild and flu-like to a more 
severe hemorrhagic fever with neurological complications (Wright et al., 2019). RVFV 
was originally isolated in East Africa, but epidemics and epizootics have since been 
observed in Northern Africa and the Arabic Peninsula (Kortekaas, 2014). Factors 
including climate change and wide distribution of suitable mosquito vectors warrant 
concerns about RVFV spreading on the global scale (Paweska & van Vuren, 2013). 
Currently, there is no safe and efficient licensed vaccine against RVFV for humans, 
though several veterinary vaccines are in use in the affected areas (WHO, 2018). 
RVFV poses a significant threat to human and animal health, making the 
development of vaccines and treatments a priority.  
RVFV is a single-stranded RNA virus that belongs to the order Bunyavirales, family 
Phenuiviridae, and genus Phlebovirus (Abudurexiti et al., 2019). The RVFV lipid 
envelope encapsulates the three RNA segments of the genome that form a 
ribonucleoprotein complex together with a viral nucleoprotein (Figure 1; Michele 
Bouloy & Weber, 2010). The medium (M) segment of the genome encodes the two 
glycoproteins, Gn and Gc, embedded in the viral envelope (Spiegel et al., 2016). Gn 
and Gc assemble into heterodimers, which in turn form the hexamers and pentamers 
that constitute the viral surface with its ring-shaped structures characteristic to 
RVFV (Halldorsson et al., 2018; Huiskonen et al., 2009).  
 
Figure 1. Overview of the 
structure of the RVFV virion. 
Genomic segments of RVFV (L, 
M, and S), nucleoprotein, viral 
RNA-dependent RNA 
polymerase, and glycoproteins 
are indicated. Image acquired 
from SIB Swiss Institute of 
Bioinformatics: ViralZone. 
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RVFV glycoproteins play a central role in several stages of the infection process. RVFV 
virions are taken up into host cells by caveolin– mediated endocytosis (Harmon et al., 
2012), which is catalyzed by RVFV glycoproteins interacting with receptors on the host 
cell surface, most importantly the C-type lectin DC-SIGN (Lozach et al., 2011). Escape 
from late endosomes is triggered by low pH, which leads to conformational changes in 
the glycoproteins. The fusion loop of Gc, a class II fusion protein, is revealed and 
inserted into the endosomal membrane, catalyzing the fusion of viral and host 
membranes (Halldorsson et al., 2018). The RVFV glycoprotein shell is also a key 
target for neutralizing antibodies (Faburay et al., 2017) and prospective antivirals 
(Atkins & Freiberg, 2017), which emphasizes the importance of resolving RVFV 
structure to near-atomic level to facilitate the design of vaccines and antiviral 
measures.  
A detailed reconstruction of the surface structure of the virion was recently obtained 
by cryo-electron microscopy (cryo-EM). Due to the innate flexibility of RVFV envelope 
proteins, the resolution of the reconstruction was limited to 7.7 Å, despite application 
of novel computational analysis techniques (Halldorsson et al., 2018). The study of the 
outer structure of RVFV is additionally complicated by the biosafety prerequisites for 
handling the pathogenic virus. Conducting structural biology work in biosafety level 3 
facilities is often time-consuming and costly (Sherman et al., 2013). Developing models 
to represent the native conformation of the surface of RVFV would help circumvent 
this challenge. 
A non-infectious virus-like particle (VLP) that lacks the viral genome but displays the 
native outer structure of RVFV has great potential as a model in structural studies. 
VLPs can be produced by using host cells to express selected viral genes, that encode 
structural protein components of the virus (Zeltins, 2013). The formation of RVFV 
VLPs in host cells has been implicated to require the expression of the viral 
nucleoprotein, in addition to envelope glycoproteins (Habjan et al., 2009). Other 
evidence suggests that RVFV VLPs can be released in the absence of the 
nucleoprotein, only less efficiently than virions or nucleoprotein-including VLPs (Piper 
et al., 2011). Indeed, VLPs based solely on heterologous expression of the two 
glycoproteins Gn and Gc have been successfully produced and imaged by transmission 
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electron microscopy (Mandell et al., 2010a). The particles seem to resemble RVFV 
virions in size and morphology, but a more in-depth structural analysis is warranted.  
The objective of this work was to assess whether RVFV VLPs, formed by expression of 
RVFV Gn and Gc in mammalian cells, could be used for modelling the outer structure 
of RVFV. In earlier studies, RVFV VLPs have been successfully expressed in various 
platforms, including insect cells (Li et al., 2016; Mandell et al., 2010b), suspension-
adapted mammalian cells (Mandell et al., 2010b), and adherent mammalian cells 
(Habjan et al., 2009; Mandell et al., 2010a). Here, we set up a VLP expression system 
by transiently transfecting adherent HEK293T cell cultures with a pLEXm-derived 
plasmid (Aricescu et al., 2006) encoding RVFV glycoproteins. Importantly, the process 
of VLP production and purification was analyzed and optimized with the aim of 
producing high-quality VLP samples for cryo-EM. Reconstructions based on cryo-EM 
data can be used to gain insights on the ultrastructure of the VLPs, and thus to assess 
the resemblance of VLPs to RVFV virions. If proving to sufficiently resemble the 
virions, VLPs have great promise for accelerating research on the structure and 
function of RVFV and related viruses. 
4 MATERIALS & METHODS 
4.1 REAGENTS AND CULTURING MEDIA 
Bacterial cultures were maintained in LB broth or on LB agar (for formulation, see 
Tables S1 and S2), supplemented with 100 µg/ml ampicillin. DMEM (for formulation, 
see Table S3) was used as the mammalian cell culturing medium. Unless otherwise 
mentioned, DMEM was supplemented with 10% FBS (Gibco), MEM non-essential 
amino acid solution (each amino acid at 0.1 mM concentration; Gibco) and 2 mM L-
glutamine (Gibco). Trypsin-(0.05%)-EDTA solution was used to detach the cells (for 
formulation, see Table S4). 
The primary antibody used for all immunodetection of RVFV Gn glycoprotein was 
monoclonal rabbit anti-RVFV Gn (300 µg/ml) (Allen et al., 2018), that recognizes the 
native conformation of RVFV Gn. HRP-conjugated anti-rabbit monoclonal antibody 
GOXRB HRP XADS (1 mg/ml; Novex) was used as the secondary antibody in dot blots. 
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For immunogold labeling of electron microscopy grids, 15 nm gold-conjugated goat 
anti-rabbit IgG (BBI International) was used, diluted to a working concentration of 
2.04 µg/ml. 
4.2 PLASMIDS, CELLS, AND CULTURE GROWTH CONDITIONS 
Escherichia coli DH5α was used as the host for plasmid propagation. Plasmid-carrying 
cultures were grown at +37 °C with shaking. The Gn/Gc-expression plasmid for VLP 
expression was constructed using pHLsec, a pLEXm-derived mammalian expression 
plasmid, as a backbone (Aricescu et al., 2006). It includes an ampicillin resistance 
gene and a gene encoding a fluorescent mTurquoise tag (Goedhart et al., 2010). The 
plasmid pKSII (Stratagene) was used as a negative control plasmid for transfection. 
HEK293T human embryonic kidney cells were grown as adherent cultures at +37 °C 
with humidification and a 5 % CO2 atmosphere. Total volume of culturing medium 
was 25 ml in 175 cm2 flasks and 10 ml in 75 cm2 flasks. Cells were split 1:10 to 1:5 at 
80–90% confluence, with 3–4-day intervals. To split the cells, culturing medium was 
removed, after which the cells were gently rinsed with 1 × PBS and detached using 3–
5 ml trypsin-EDTA. The detached cells were resuspended by adding 10 ml culturing 
medium, and excess trypsin was removed by centrifuging the cells (300 × g, 5 minutes, 
+20 °C) and removing the supernatant. The cell pellet was resuspended in 10 ml of 
culture medium, after which cell count of the suspension was determined and a 
suitable volume was pipetted into a flask with fresh medium to start the new culture. 
The cell density of the resuspension was determined with TC20 cell counter (Bio-Rad). 
A 10 µl aliquot of a 1:1 mixture of trypan blue solution and cell suspension was 
pipetted in a chamber of a cell counting slide. All cell counts reported here are 
averages of at least two parallel cell counts. 
Frozen cell stocks were stored in a mechanical freezer at – 75 °C. The stocks were 
prepared from fresh cultures at approximately 90% confluence. To prepare a stock, the 
cells were washed with 25 mL PBS, and detached using 3 mL trypsin-EDTA. 10 mL 
culture medium was added to the detached cells, and the suspension was centrifuged 
at 300 × g for 5 minutes. The cell pellet was resuspended in 5 mL freezing medium 
(DMEM with 20% FBS, 10% DMSO) and aliquoted into 1 mL cryotubes. The stocks 
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were frozen by storing them in a cell freezing apparatus (Mr. Frosty™, ThermoFisher 
Scientific) with isopropanol at −75 °C, for 5.5 hours to overnight, after which they 
were transferred to a regular container at the −75 °C freezer. 
A new culture was started from a frozen cell stock by thawing it rapidly at +37 °C and 
pipetted into 5 ml fresh culturing medium. The cell suspension was centrifuged at 300 
× g, +20 °C, for 3 minutes, to remove DMSO from cells. The cell pellet was 
resuspended into 6 ml fresh culturing medium and transferred into a 25 cm2 flask for 
incubation. 
4.3 CLONING AND PLASMID PURIFICATION 
The Gn/Gc-expression plasmid had been constructed prior to this thesis work by 
ligating a synthetic cDNA fragment corresponding to the RVFV clone 13 M segment 
region encoding Gn and Gc into the plasmid backbone. A tag-free version of the Gn/Gc-
expression plasmid with the same components excluding the mTurquoise gene had 
also been constructed. The correct composition of the plasmids had been confirmed by 
sequencing.  
Plasmids were extracted from 2 L bacterial cultures grown for 18–22 h using 
EndoFree Plasmid Mega Kit (Qiagen), according to the manufacturer’s instructions. 
The DNA concentration of the plasmid preparation was measured with BioPhotometer 
(Eppendorf). Aliquots of the DNA sample being measured were diluted with elution 
buffer as needed for the A260 value to be in the range for reliable measurements (0.1–
1). 
The plasmid pKSII (Stratagene) was used as a negative control plasmid for 
transfection. It was propagated in the same host strain as the Gn/Gc-expression 
plasmid. To extract the plasmid, a 50-ml culture was started in LB broth 
supplemented with 100 µg/ml ampicillin and incubated for 18 hours at +37°C with 
shaking. Cells were harvested by centrifugation at 3,220 × g, +20°C, for 10 minutes, 
and the pellet was stored at −20°C overnight. The pellet was thawed on wet ice, and 
plasmids were extracted using PureLink Fast Low-Endotoxin Midi Plasmid 
Purification Kit (Invitrogen), following the manufacturer’s protocol. 
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Plasmid preparations were sterilized for transfection by chloroform treatment. The 
mass of plasmid required for transfection was diluted into 100 µl H2O and mixed 
thoroughly with an equal volume of 100% chloroform. The phases were separated by 
centrifugation at ~13,000 × g for 5 minutes, and the top (aqueous) phase containing 
the DNA was removed by pipetting and used for transfection.  
Polyethyleneimine (PEI) was used to transfect mammalian cells with the Gn/Gc- 
expression plasmid, following the protocol described by Aricescu et al. (2006), and 
cultured in a medium containing 10% FBS post-transfection. Unless otherwise 
mentioned, 50 µg DNA and 100 µl PEI (1 mg/ml) were used to transfect a culture in a 
175 cm2 flask. When using smaller cell culture flasks, DNA and PEI amounts were 
scaled down proportionately to the surface area of the flask. 
4.4 CONCENTRATION OF VLP SAMPLES 
4.4.1 Concentration with reverse dialysis using PEG 
Concentration was performed in 12–14 kDa MWCO regenerated cellulose membrane 
tubing (length 25 cm, diameter 29 mm), that was sealed using clamps supplied by the 
manufacturer of the membrane. The tubing containing the sample was laid on top of a 
1-cm layer of PEG (35 kDa), and PEG was also added on top of the tubing. The sample 
was concentrated for 3.5 hours until the volume had reduced from 112 ml to ~6 ml, 
after which it was removed from tubing.  
4.4.2 Concentration and buffer exchange by ultrafiltration 
Amicon centrifugal filters (Merck Millipore) with the nominal molecular weight limit 
of 100K were used to concentrate VLP samples. Ultrafiltration apparatuses with 
different capacities were used depending on sample volume. Before loading the 
sample, filters were rinsed with buffer. The detailed centrifugation parameters for 
each centrifugal filter size are listed in Table S5. To remove CsCl from the CsCl 
density gradient fractions, up to maximum loading volume 1 × PBS was added into the 
filter on top of the concentrated sample, and the concentration step was repeated.  
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4.5 VLP SAMPLE PURIFICATION 
VLPs were harvested from cell cultures by removing the culturing medium and 
replacing it with fresh medium. The harvested media were clarified by centrifugation 
at +4 °C, 3000 × g, for 30 minutes, to remove any cells or larger cell remnants. All VLP 
samples were stored at +4 °C following this step.  
4.5.1 Dialysis 
The cellulose ester dialysis tubing (diameter 20 mm) had the MWCO of either 300 kDa 
or 1000 kDa. It was cut to a size suitable for accommodating the sample, and pre-
treated by soaking in H2O for 15 minutes, after which the sample was loaded into the 
membrane tubing. Dialysis was performed at +4 °C with magnetic stirring against 
200× sample volume 1 × PBS for 22.5 h. The dialyzed sample was recovered by 
pipetting it from the tubing.  
Possible paraformaldehyde fixation during dialysis was performed by adding 0.02 % 
(v/v) electron-microscopy grade paraformaldehyde in the dialysis buffer. The sample 
was dialyzed against the paraformaldehyde solution for 22.5 h, after which excess 
paraformaldehyde was removed from the sample by dialysis against 1 × PBS. 
Slide-A-Lyzer Dialysis Flasks, 10 K MWCO (Thermo Fischer Scientific), were soaked 
for 2 minutes in dialysis buffer prior to use. The sample was loaded in the flask and 
air was removed by submerging the flask in buffer before screwing on the cap. The 
samples were dialyzed against 40× sample volume 1 × PBS at +4 °C with magnetic 
stirring.  
4.5.2 Equilibrium density ultracentrifugation with CsCl  
CsCl solution used as the gradient material was prepared at the latest a day before 
the ultracentrifugation run by dissolving CsCl in 1 × PBS. PBS was added, until 
desired density (as determined by weighing 100 µl aliquots of the solution), ranging 
from 1.25 to 1.27 g/cm3, was reached. The samples were ultracentrifuged using Sorvall 
TH660 rotor (for 4 ml tubes) or TH641 rotor (for 12 ml tubes). Either 1 or 3.7 ml of 
sample was added on top of either 3 ml or 8 ml of CsCl solution, respectively. The 
tubes were balanced by adding 1 × PBS. Ultracentrifugation was performed in a 
Sorvall WX Ultra 80 centrifuge at 68 706 × g, at +15 °C, for 16–17 hours. After 
ultracentrifugation, each sample was divided into 0.4-ml (TH660 rotor) or 1-ml 
12 
 
(TH641 rotor) fractions by pipetting from the surface. The fractions were weighed to 
determine their densities. 
4.6 PROTEIN ANALYSES 
4.6.1 Dot blotting 
Samples were blotted manually on an Immobilon-P (0.45 µm pore size) polyvinylidene 
fluoride membrane. Before blotting, the membrane was activated in methanol for 15 
seconds, rinsed in H2O for 2 minutes, and in 1 × PBS for 5 minutes. The blotting stack 
was assembled from bottom to top starting with a few sheets of tissue paper, then two 
sheets of Whatman 3MM filter paper cut to the size of the membrane (the one on top 
was pre-wet with 1 × PBS), and finally the blotting membrane. 2–5 µl samples were 
pipetted on the membrane. When samples had absorbed into the membrane, it was 
either dried between two sheets of filter paper, or it was transferred directly to the 
blocking step of immunodetection. 
4.6.2 Immunodetection 
In case the membrane had been dried at +20 °C, it was soaked in methanol for 5 
minutes prior to blocking. The wet membrane was blocked with 3% (w/v) dry skim 
milk in 1 × PBS, with 0.05% (v/v) polysorbate-20, at +20 °C for 1 hour. Blocking was 
followed by 1 hour of incubation with primary anti-Gn antibody (diluted 1:3000 in 
blocking buffer), 3 × 5-minute washes with 1 × PBS, 30 minutes of incubation with 
secondary HRP-conjugated antibody (diluted 1:5000 in blocking buffer), and 3 × 5-
minute washes with 1 × PBS. The HRP conjugate was detected with ECL Western 
Blot substrate (Pierce), prepared according to the manufacturer’s instructions. The 
membrane was incubated under the substrate solution for 1 minute. The blots were 
imaged with Bio-Rad ChemiDoc Imager, using the chemiluminescence protocol, 10–30 
minutes after the application of substrate on the membrane. 
4.6.3 Protein concentration measurements 
Protein concentrations were measured using Bradford’s method (Bradford, 1976). 
Samples were diluted in 20 mM Tris-HCl buffer (pH 7.5). Standard samples were 
prepared by diluting BSA to 1, 2, 3, and 4 µg/100 µl, and plain buffer served as a zero. 
100 µl Instant Blue – Coomassie reagent (Expedeon) was added to each 100 µl sample, 
and absorbance values were measured with a plate reader at 595 nm. Two replicates 
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were made of each sample and standard. Measurements that were not in the range of 
the standard curve were discarded (in favor of other dilutions of the same sample). 
4.7 TRANSMISSION ELECTRON MICROSCOPY 
VLP samples were negatively stained for transmission electron microscopy (TEM). 3–
10 µl sample was pipetted on a glow discharged, Formvar- and carbon coated 200 
mesh Cu-grid and incubated for 5 minutes at ~+20 C°. Grids were washed twice in 100 
µl water droplets and stained in 15 µl 2% uranyl acetate (pH 4) droplets twice, or a 30 
µl droplet of 1% ammonium molybdate (pH 7), and dried using filter paper.  
For immunogold labeling of the VLPs, grids were treated with antibodies before 
staining as follows. The grids were washed in 30 µl 1 × PBS, dried with filter paper, 
and blocked in a 30 µl droplet of 3% BSA for 15 minutes. Next, grids were incubated 
for 45 minutes in a 30 µl droplet of primary antibody solution (anti-RVFV Gn, solution 
diluted 1:500). After incubation, the grids were washed in 6 × 30 µl droplets of 1 × 
PBS. The grids were incubated in 25 µl of immunogold-labeled secondary antibody 
solution for 45 minutes. The grids were washed in 6 × 30 µl droplets of 1 × PBS and 
incubated in the last wash buffer droplet for 2 minutes before proceeding to staining. 
The grids were imaged using a transmission electron microscope, either a JEOL1400 
at an accelerating voltage of 80 kV, or a TECNAI F20 with an accelerating voltage of 
200 kV. 
4.8 IMAGE PROCESSING AND ANALYSIS 
Dot blot images were analyzed by quantifying the detected signals using ImageJ. The 
colors of the dot blot image were inverted, background was reduced as much as 
possible without losing sensitivity, and the blotted areas were selected individually 
with a circular tool for measurement of integrated density, a unit measuring the 
signal intensity of the pixels in the selected area.  
Transfected mammalian cell cultures were imaged 24 hours post-transfection using 
bright field and blue channels of a FLoid Cell Imaging Station (Thermo Fischer 
Scientific). Raw images from the two channels were merged to one image using 
ImageJ, with no further processing. 
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5 RESULTS 
The aim of this work was to explore different production protocols to maximize RVFV 
VLP yield, and to optimize purification to obtain high-quality samples for electron 
microscopy analyses. The expression system was set up by transfecting human 
embryonic kidney cells with a mammalian expression plasmid based on pHL-sec, a 
vector optimized for expression of secreted proteins in mammalian cells (Aricescu et 
al., 2006). The VLP expression plasmid had been constructed by cloning an insert 
encoding RVFV glycoproteins Gn and Gc and the gene coding for the fluorescent 
marker mTurquoise into the vector (Figure 2). In this work, transfection and VLP 
harvest protocols were optimized, and different methods for purifying and 
concentrating VLP samples were examined for their efficiency (Figure 3).  
 
 
 
 
 
Figure 2. Features of the Gn-Gc expression plasmid. A) A map of the plasmid. Key elements of the plasmid 
are indicated in the map: the insert (3.2 kb region of the RVFV M segment, encoding the RVFV glycoproteins), 
fluorescent tag and poly-His tag genes, selection gene, and elements enhancing mammalian expression. Important 
restriction enzyme recognition sites of the multiple cloning site are marked in italics. The apparent sizes of the 
regions are not to scale. B) A linear map of the insert and mTurquoise gene. The insert includes a Kozak 
sequence and the regions coding for a signal peptide and the glycoproteins Gn and Gc from the RVFV clone 13 M 
segment. Sizes of the regions and their respective products are displayed in kilobases and amino acids (apparent 
sizes not to scale). Key restriction enzyme recognition sites indicated in italics. 
 
A                                                   B 
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Figure 3. The workflow of VLP sample processing and targets of optimization. Steps of the process are 
bolded, and the parameters that were compared and optimized are in italics. 
5.1 OPTIMIZATION OF VLP PRODUCTION 
5.1.1 Plasmid gene expression detected by fluorescence microscopy 
The VLP expression plasmid includes a gene coding for a fluorescent tag, mTurquoise, 
that is co-expressed with the VLP glycoproteins. The possibility of exploiting this tag 
for monitoring gene expression in cell cultures was explored by imaging transfected 
cultures by fluorescence microscopy. As negative controls for mTurquoise expression, 
cultures transfected with H2O or a version of the VLP expression plasmid from which 
the mTurquoise gene had been excised were set up and imaged in parallel. The 
cultures were transfected following standard protocol.  
The cells were imaged 24 hours post-transfection using the bright field and blue 
channels of the microscope. The two channels were merged using ImageJ software 
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(Figure 4). In the samples transfected with the VLP expression plasmid, expression of 
the gene of mTurquoise-tag can be observed as fluorescent dots in the cells detected by 
the blue channel. In contrast, no blue signals discernible from the background are 
found in the negative controls, confirming that cell cultures transfected with a plasmid 
encoding mTurquoise can be differentiated from other cultures using fluorescence 
microscopy (Figure 4). These results show that success of transfection and plasmid 
gene expression can be confirmed by microscopy before any VLP purification 
procedures, and without detecting VLP proteins specifically. 
 
 
 
 
 
 
Figure 4. Success of transfection with VLP expression plasmid can be observed by fluorescence 
microscopy. Columns from left to right: Controls transfected with H2O, controls transfected with tag-free VLP 
expression plasmid, controls transfected with VLP expression plasmid encoding the mTurquoise tag. Expression of 
the mTurquoise gene in the plasmid causes the distinct fluorescent signals in the blue channel of FLoid, here cyan-
colored. The images are composites of blue and white channel raw images from FLoid. The two photographs per 
treatment are taken from two separate culture flasks. 
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5.1.2 Highest RVFV Gn yield by transfecting cells with recommended 
plasmid amount 
For optimization of the transfection procedure, different plasmid-to-cell ratios were 
tested. The normal 50 µg of DNA was compared with 25 µg and 75 µg of DNA per 175 
cm2 culture flask of cells, as well as a negative control with no plasmid. Four cell 
cultures were used for the experiment (n = 1). Seeding cell number for the cultures 
used in this work was an average of 3.70 × 105 cells / cm2 of growth area (standard 
deviation ±1.12 × 105) based on live cell count measurements performed for cultures 
used in three separate transfections. The cells were transfected following standard 
protocol. Supernatant samples were harvested at 12, 24, 36, 48, and 72 h. The samples 
were centrifuged, concentrated by ultrafiltration to 4% of the original volume, and 
analyzed by a dot blot (Figure 5). No unspecific detection by the anti-Gn antibody was 
observed in the blot, based on the complete absence of signal in the negative control. 
However, no signal can be observed in the positive controls, either, suggesting that 
there was a problem in the preparation of the controls. 
Based on the results (Figure 5), it seems that the recommended plasmid-to-cell ratio 
(Aricescu et al., 2006) is also optimal for the expression of the VLPs. With higher 
DNA-to-cell ratios (75 µg), the expression begins as more or less equally strong than 
that of the samples transfected with the recommended ratio. At 72 hours, however, the 
Gn expression seems to drop in the samples transfected with 75 µg of DNA. Using only 
half of the recommended amount of plasmid DNA in transfection (25 µg) seems only to 
decrease expression, as expected. The recommended ratio of 50 µg plasmid DNA per 
175 cm2 cell culture flask was used in all subsequent transfections. 
5.1.3 RVFV Gn expression highest at 36-72h 
In order to study the production of VLPs at different time points in adherent 
mammalian cell cultures, Gn expression levels were analyzed in time points 12 h, 24 
h, 36 h, 48 h, and 72 h. VLPs were produced in mammalian cells by transfecting the 
cells with the VLP expression plasmid, or H2O (negative control for expression). 
Supernatant samples were harvested at the indicated times, centrifuged to remove 
cells, concentrated by ultrafiltration to approximately 4% of original volume, and 
analyzed with a dot blot assay (Figure 5A). The signals in the dot blot image were 
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quantified densitometrically using ImageJ software (Figure 5B). The signal intensity 
analysis helps gauge the best harvest times for optimal yield of RVFV VLPs. Some 
level of Gn expression is observed already at 24 hours (Figure 5), but the most 
favorable harvest times seem to be at 36, 48 and 72 hours, when the expression of 
RVFV Gn is at its peak. There is no notable difference between 36, 48, and 72 hours.  
Figure 5. Effect of harvest times and plasmid DNA amounts on Gn expression. A) Dot blot analysis. 
Samples harvested at 5 time points and from 4 differently treated cell cultures (with varying amounts of plasmid 
used in transfection). 5 µl of each concentrated sample was blotted, n = 1. The positive controls (Gn dilution series) 
were not visible in the blot image. B) Measurements from a densitometric analysis of the dot blot image (A). 
The graph displays the relationship between Gn signal intensity and harvest time in the 4 cell cultures. On the 
vertical axis, IntDen (integrated density) represents color and abundance of pixels in a certain area as measured by 
the image analysis software. 
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5.2 VLP PURIFICATION CHALLENGING BY EQUILIBRIUM GRADIENT 
ULTRACENTRIFUGATION 
Equilibrium density gradient ultracentrifugation can be used to separate biological 
materials based on differences in density (Frei, n.d.). To examine the possibility of 
purifying and concentrating VLPs by applying a CsCl equilibrium density gradient, 
and to control for factors that might affect the performance of this method, four 
different samples were prepared for ultracentrifugation. The pore size of the dialysis 
membrane determines how much material is removed from the sample during 
dialysis, and the role of fixatives is to stabilize the structure of VLPs. The effect of the 
use of a chemical fixative as well as the pore sizes of the dialysis membranes on the 
movement of the particles in CsCl gradient were assessed.  
75 ml VLP culture supernatant and 25 ml negative control culture supernatant were 
harvested 48 h post-transfection. The samples, excluding negative control, were pooled 
to eliminate the possible differences in expression between individual cell culture 
flasks. The VLP culture supernatant sample was divided into 25 ml aliquots that were 
subjected to three different treatments. One of the aliquots was dialyzed using a 
membrane with a molecular weight cutoff value (MWCO) of 1,000 kDa (sample 1000). 
The other two aliquots were dialyzed using a membrane with a MWCO of 300 kDa. 
One of these was dialyzed without a fixative (sample 300), while the other was treated 
with a fixative by adding 0.02% paraformaldehyde in the dialysis buffer (sample 300-
PFA). The negative control (sample C) was dialyzed with a 300 kDa membrane. 
After dialysis, the samples were concentrated by ultrafiltration, separated in an 
equilibrium density gradient using CsCl solution with an average density of 1.25 
g/cm3, and fractionated. Before fractionation, centrifugation tubes were examined 
under white light to find any light scattering zones that could correspond to VLPs, but 
no zones absent from the negative control were observed in the samples. A graph 
plotted from the densities of each fraction (Figure 6A) shows that the linear density 
gradient formed successfully during the ultracentrifugation, with only slight 
irregularities. 
To analyze the fractions using immunodetection, they were concentrated by 
ultrafiltration. A de-salting step was applied in the concentration process to remove 
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most of the CsCl from the fractions. The fractions were analyzed in a dot blot assay to 
examine the abundance of RVFV Gn in each fraction (Figure 6B). Strong Gn signals 
were detected in many fractions in all transfected samples, especially in low density 
fractions (1-6), with the signals gradually weakening towards the bottom of the tube. 
Differences between sample treatments were not pronounced. It might be worth 
noting that in sample 1000, Gn signal was observed in only 9 fractions instead of 10 
(as was the case of samples 300 and 300-PFA). PFA-treatment did not seem to affect 
the density of the particle and thus the migration of the particles in the gradient. 
Based on these results, it is difficult to exactly determine the fraction where the VLPs 
can be found, as the signal seems equally strong across several fractions (Figure 6B; 
sample 300, 2-4). The three strongest signals correspond to density values in the range 
of 1.06–1.13 g/cm3 (Figure 6).  
 
Figure 6. Analysis of fractions from CsCl density gradient ultracentrifugation. Four samples were 
ultracentrifuged and fractionated: a VLP expression sample dialyzed with a 300 kDa MWCO membrane (300), a 
VLP expression sample dialyzed with a 300 kDa MWCO membrane and fixed with PFA (300-PFA), a VLP expression 
sample dialyzed with a 1,000 kDa membrane (1000), and a negative control sample, with no DNA used in 
transfection, dialyzed with a 300 kDa MWCO membrane. A) Density gradient plotted from density 
measurements of fractions. The density of each fraction from 1 to 10 is plotted in the y-axis. The gradients display 
some irregularities but are roughly linear. B) Dot blot analysis of fractions. Gn protein samples diluted to 64 and 
32 ng/µl served as positive controls for immunodetection. Gn signal is strong across several fractions in all 
fractionated samples.  
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5.3 ULTRAFILTRATION LEADS TO BETTER FRACTIONATION OF RVFV GN 
THAN DIALYSIS AGAINST PEG 
The volumes of the dialyzed samples of cell culture medium needed to be reduced for 
ultracentrifugation. Additionally, analyses based on immunodetection required 
samples with higher concentrations of RVFV Gn than that of the dialyzed, 
unconcentrated medium, so that the Gn protein on the VLP surface could be detected. 
Two methods for reducing sample volume were compared by immunodetection of 
RVFV Gn present in the samples after the respective concentrating processes and 
ultracentrifugation. The methods tested here were ultrafiltration by centrifugal filters 
and reverse dialysis against polyethylene glycol (PEG) through a semipermeable 
membrane. 
To examine the possibility of either treatment affecting the separation of the sample 
in a density gradient, samples concentrated by the two methods were purified by 
equilibrium gradient ultracentrifugation. The VLP samples were produced in cell 
cultures, following standard protocols. Culture supernatants harvested at 24, 48, and 
72 h post-transfection were pooled together, resulting in 225 ml supernatant. The 
supernatant sample was dialyzed in a regenerated cellulose membrane flask with 10 
kDa MWCO against 1 × PBS. The dialyzed sample was divided in two 112 ml aliquots. 
One of these was concentrated to 6 ml by ultrafiltration using an Amicon Ultra-15 100 
K unit. The other aliquot was concentrated by PEG dialysis. The sample was 
transferred to a 12–14 kDa regenerated cellulose membrane and the sample was 
concentrated to 6 ml.  
A negative control had been prepared in parallel with the VLP expression cultures by 
starting a new culture in a 75 cm2 flask and transfecting it with 7.5 µg of control 
plasmid (pKSII) that does not encode any RVFV proteins. Harvests were performed as 
described for the VLP samples, resulting in 30 ml of sample, which was not dialyzed, 
but concentrated with an Amicon Ultra-15 100K device to 1.5 ml.  
The samples were subjected to CsCl density gradient ultracentrifugation, using CsCl 
solution with the average density of 1.27 g/cm3. Each sample was divided in two equal 
aliquots whereas the negative control with a smaller volume of starting material in 
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only one. Following ultracentrifugation, the samples were divided into 1 ml fractions 
(Figure S1) and concentrated by ultrafiltration.  
The fractions concentrated by ultrafiltration were analyzed by immunodetection in a 
dot blot (Figure 7). There was an unusually high background signal in the blot, but 
general interpretation of the results was still possible. Both samples showed poor 
fractionation with regard to Gn, with the slight difference that the Gn in the PEG-
dialyzed sample was found even in the densest fractions (10–12). In the sample 
initially concentrated with ultracentrifugation, Gn was not detected in these three 
bottom fractions, excluding a weak signal in the bottom fraction. There is a possibility 
that PEG treatment interferes with VLP movement in equilibrium density gradient. 
 
Figure 7. Effect of concentration methods in Gn content of CsCl gradient fractions. Dot blot analysis of 
fractions. 2µl of each fraction was blotted. Three samples had been fractionated: a sample concentrated by PEG 
dialysis (PEG), a sample concentrated by ultrafiltration (Ultrafiltration) and a negative control sample, with no 
DNA added in transfection, concentrated by ultrafiltration (Negative control). A Gn dilution series served as the 
positive control. (Only 32 ng/µl dilution visible). In the sample concentrated by ultrafiltration, Gn was not found in 
fractions 9 and 10, whereas in the PEG dialyzed sample Gn was found in all fractions.  
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5.4 VLPS DETECTED BY IMMUNO-EM IN PURIFIED AND CONCENTRATED 
SAMPLES 
Selected fractions obtained from equilibrium gradient separation in this work were 
analyzed with electron microscopy (EM) to examine their VLP content. Fractions with 
a high Gn content (based on immunodetection results; see Figures 6 and 7) were 
chosen for grid preparation and EM. The protein concentrations of the fractions were 
determined by Bradford’s method. During microscopy, particles with a diameter of 
roughly 100 nm were searched, as the size of RVFV particles has been reported to be 
80–120 nm (Halldorsson et al., 2018). 
Fractions 2-5 (Figure 6) from the CsCl gradients of samples 300, 300-PFA, and 1000, 
were selected, diluted to 1 mg/ml and stained with uranyl acetate for EM analysis. In 
the micrographs, various types of materials can be seen, possibly including cell 
membrane remnants, extracellular vesicles (EVs), or VLPs (Figure 8). Other vesicle 
structures, such as EVs secreted by the host cells, might be falling in the same range 
of size and shape as the VLPs (van Niel et al., 2018). Thus, differentiating between 
VLPs and EVs reliably was not possible by this method. In fraction n:o 5 of the PFA-
treated sample dialyzed with a 300 kDa membrane, one very spherical vesicle with a 
regular surface structure could be observed (Figure 8A). Based on its size (~100 nm), it 
could be a VLP, but without means to analyze the surface structure of the vesicle more 
closely, its identity could not be conclusively determined. 
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Figure 8. TEM micrographs of samples stained with 2% uranyl acetate. A) A possible VLP in PFA-fixed CsCl 
fraction 5 from a 300 kDa-dialyzed sample (indicated with an arrow). Size of the particle corresponds to RVFV 
particle size of approximately 100 nm. B) 1000 kDa -dialyzed sample, CsCl fraction 3. In this micrograph, diverse 
structures can be observed that may be large proteins, cell membrane fragments, VLPs, or extracellular vesicles. 
Two independent sets of VLP samples were analyzed by immunoelectron microscopy 
(immuno-EM), which is a way of identifying the RVFV VLPs specifically in the 
samples. The VLP sample grids can be treated with the RVFV Gn antibody, and a 
secondary antibody conjugated with electron-opaque gold nanoparticles to enable 
detection of antibody binding by EM (Murtey, 2016). Differentiation between VLPs 
and extracellular vesicles is possible by observation of the vesicles associated with gold 
particles. For the purposes of this analysis, any vesicle-like structure with several gold 
particles visibly attached was considered a VLP.  
The first set of immuno-EM samples was selected from the fractions that had already 
been analyzed by negative staining TEM. These had been dialyzed with cellulose ester 
membranes (pore size either 300 kDa or 1000 kDa), concentrated by ultrafiltration, 
run into a CsCl gradient, and fractionated. Fractions 2-5 from all samples, except the 
negative control, were analyzed (immunodetection analysis of fractions, see Figure 6). 
Microscopy of the first set of samples revealed very few VLPs, one of which is shown in 
Figure 9D. Otherwise, the gold particles found in the samples were associated with 
diverse non-spherical membrane structures, or with no visible structure at all.  
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Several VLPs were observed by EM in the second set of samples (Figure 9, A-C) 
originating from a separate batch of transfection. The samples were dialyzed with a 
dialysis flask (regenerated cellulose membrane, MWCO of 10 kDa), concentrated by 
either ultrafiltration or PEG reverse dialysis, fractionated following a CsCl density 
gradient ultracentrifugation (Figure 7), and concentrated by ultrafiltration before 
microscopy. The fractions were diluted 1:4 in 1 × PBS to reduce sample viscosity, and 
10 µl sample was then loaded on the grid. VLPs found in this round of microscopy 
were irregularly shaped and most often appeared as aggregates of three to five 
particles (Figure 9, A-C). VLPs were found more often, compared to the previous set of 
samples, but they were still not sufficiently abundant on the grids for efficient cryo-
EM data collection. Preliminary observations made by cryo-EM of these samples (data 
not shown) revealed a high density of proteins, whereas VLP-like structures were 
scarce.  
 
Figure 9. TEM micrographs of immunogold-labeled samples stained with 1% ammonium molybdate. The 
electron-opaque gold particles mark the outlines of VLPs. The sizes of the particles correspond to RVFV size (around 
100 nm). A) – C) Sample dialyzed with a regenerated cellulose membrane, 10 kDa, concentrated by ultrafiltration, 
CsCl fraction 5. D) TEM micrograph of immunolabeled VLPs from 300 kDa dialyzed, unfixed sample, CsCl fraction 
2.  
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6 DISCUSSION 
VLPs are a promising alternative for studying surface structures of pathogenic viruses 
such as RVFV, the handling of which would otherwise be very laborious. VLPs are 
non-infectious and potentially easy to both produce and purify. Their envelope is 
expected to look very similar, if not identical, to that of an infectious virus, including 
RVFV virion. In earlier studies, contradicting results have been obtained on whether 
expression of RVFV Gn and Gc, without other viral components, can lead to 
production of RVFV VLPs (Habjan et al., 2009; Mandell et al., 2010a). The possibility 
of the purification of RVFV VLPs suitable for cryo-EM analyses had not been 
examined in these studies. For this purpose, the initial yields of VLPs should be high, 
and the elimination of EVs and other membranous material abundant in the samples 
might be difficult without damaging the VLPs.  
This work describes the attempts to optimize protocols for purification of RVFV VLPs 
produced in mammalian cell cultures for structural analyses. In this work, RVFV 
VLPs were identified by immunoelectron microscopy, confirming that the VLPs can be 
processed for electron microscopy analyses using the methods described here. There 
are still open questions remaining, most importantly those of VLP yield and sample 
purity, which should be answered before the methods can be applied in a larger scale 
for structural studies. 
Developing the methods for the production and purification of RVFV VLPs involves 
some challenges. One of them is the very nature of VLPs: their lack of genome 
prevents their detection and quantification with methods traditionally applied for 
viruses, such as infectivity assays and nucleic acid analyses (Steppert et al., 2017). In 
this work, the expression of viral genes cloned in a mammalian expression vector for 
VLP production was initially confirmed by fluorescence microscopy. The quality of the 
images was low, which might be attributed to the fact that the parameters of the blue 
channel (excitation 390/40 nm, emission 446/33 nm) used for capturing mTurquoise 
fluorescence overlaps poorly with the respective spectra of mTurquoise (excitation 434 
nm, emission 474 nm) (Goedhart et al., 2010). Images more suitable for quantitative 
applications may be obtained by using a fluorescence microscope that has a filter set 
for mTurquoise. 
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Antibody-based detection was used to evaluate the presence and relative abundance of 
VLPs. The anti-RVFV-Gn antibody that was used here (Allen et al., 2018) exclusively 
recognizes the native conformation of RVFV Gn. This precludes applying 
immunodetection methods that denature the target proteins, such as Western blot 
(Ilona Rissanen, personal communication). Therefore, dot blots were used in this work 
for Gn detection. However, interpretation of the results obtained by immunodetection 
should be cautious, because in addition to VLPs, the Gn protein antigen used for the 
detection during the purification optimization is most likely present in nonspecific 
membrane structures as well. The presence of VLPs was confirmed using immuno-
EM, which allows Gn proteins of VLPs to be distinguished from Gn bound to other 
membrane structures. In the future, more precise and less invasive methods, such as 
nanoparticle tracking or multi-angle light-scattering detection, could be applied for 
VLP quantification (Steppert et al., 2017). Nevertheless, Gn is a strong indicator for 
the presence of VLPs, and the expression of RVFV glycoproteins is a prerequisite for 
VLP formation.  
In earlier research by Mandell et al. (2010a), RVFV Gn expression in a comparable 
HEK293 platform was determined to be highest 36–60 hours post-transfection. Using 
a modified cell line in the adherent cultures (HEK293-gag cells that express Moloney 
murine leukemia virus gag protein) did not considerably enhance VLP production 
(Mandell et al., 2010a), and for this reason, gag-producing cell lines were not tested in 
this work. HEK293T cells were used in the experiments described here, as 
recommended for the pLEXm-derived vector used (Aricescu et al., 2006). For our 
expression system, the best times for harvesting the VLP samples were estimated to 
be 36–72 hours post-transfection, based on the results of the preliminary VLP 
production experiment. This is in accordance with the results obtained by Mandell et 
al (2010a). The DNA-to-cell ratio recommended by the original publication describing 
the transfection protocol used in this study (Aricescu et al., 2006) seemed optimal for 
strong and sustained Gn expression. 
When evaluating the results from the time course and transfection experiments, it 
should be considered that Gn controls were not visible on the blot, possibly owing to a 
mistake in the preparation of controls. Therefore, it remains open whether there is a 
linear relationship between Gn concentration and signal intensity in the dot blot. This 
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should be determined in future experiments by including a standard curve based on 
serial dilutions of Gn. Moreover, statistical analysis to assess whether the differences 
between treatments are significant could not be performed based on these results. 
This is due to the time frame of the thesis that did not allow repeating the experiment 
or producing replicate samples. However, these preliminary results will help guide the 
design of further experiments. To further test the effects tentatively observed here, 
simultaneous culturing of several separate cell cultures for each treatment would 
enable statistical analyses of the results. Cell density of the cultures should also be 
standardized to ensure comparable protein production between cultures. Additionally, 
the VLP preparations obtained from the time course experiment could be analyzed by 
immuno-EM to examine the abundance of intact VLPs that egress from the cells 
during each time window. 
Effective purification and concentration of samples is essential to obtain high-quality 
samples for structural studies by cryo-EM (Stark & Chari, 2016). Some degree of VLP 
loss during purification is inevitable, regardless of the purification methods used, but 
certain methods might perform more efficiently than others. After removing cells from 
samples of culturing medium by low-speed centrifugation, large cell remnants, such as 
membrane fragments and extracellular vesicles, can still be found in abundance. The 
elimination of these materials by methods such as dialysis against PBS and 
equilibrium density gradient ultracentrifugation considerably facilitates examining 
the VLPs by EM. The permeability (pore size) of dialysis membranes composed of the 
same material did not seem to have a notable effect on purification, whereas it seemed 
that membrane material of the dialysis tubing might affect VLP yield, based on 
preliminary observations in immuno-EM. Fewer VLPs were detected by EM in 
samples dialyzed using cellulose ester membranes, compared with regenerated 
cellulose membranes, although this contrast might depend entirely on the different 
volumes of starting material. However, to avoid loss of VLPs during dialysis, the effect 
of dialysis membrane composition should be investigated systematically by dialyzing 
similar volumes of starting material with dialysis membranes of different material but 
equal permeability. 
The reduction of dialyzed supernatant volume prior to ultracentrifugation was 
approached with two alternative methods, of which PEG dialysis seemed to perform 
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more weakly compared to ultrafiltration. After ultracentrifugation, Gn signal in the 
PEG-dialyzed sample was divided across all fractions, while signal was not found in 
the bottom three fractions of the ultrafiltrated sample. This suggests that PEG might 
interfere with sample fractionation in some manner. One caveat of this experiment 
was that the two concentration methods were not analyzed directly after the 
concentration processes, preventing feasible quantitative comparisons of total Gn 
content between samples. This should be addressed by analyzing the samples before 
any downstream processing by dialysis of ultracentrifugation. Further analyses, 
including comparison with other concentration methods, such as vacuum 
concentration, could be useful in determining the best method of reducing sample 
volume.  
The results obtained here indicate that VLPs do not separate readily in a CsCl density 
gradient, rendering the benefits of this purification step uncertain. RVFV buoyant 
density has been reported as 1.16–1.18 g/ml (Ikegami et al., 2005), or 1.20–1.21 g/ml 
by Springer Index of Viruses (Michèle Bouloy, 2011). Buoyant densities of 
extracellular vehicles (EVs) range from 1.08 g/ml to 1.22 g/ml (Renner et al., 2018). 
Therefore, many EVs could co-localize with VLPs in CsCl gradient. There is a 
possibility that the samples analyzed here were too concentrated and crowded with 
cell debris, EVs, and VLPs, which could have prevented efficient separation of sample 
contents. It is also likely that the presence of Gn signal in immunodetection does not 
directly correlate with VLPs, as the signal might also originate from Gn associated 
with other membrane structures. 
Instead of equilibrium density gradient ultracentrifugation, VLPs could be extracted 
from samples by pelleting them through a sucrose cushion, as has been done with 
RVFV virions (Halldorsson et al., 2018) and RVFV VLPs (Mandell et al., 2010a) 
before, but this would risk damaging the possibly fragile structure of the VLPs. Unless 
fine-tuning of the purification protocols described in this thesis improves the quality of 
VLP samples, alternative purification methods, that are not based on 
ultracentrifugation, should be considered. Recently, a combination of size-exclusion 
and heparin affinity chromatography was successfully applied for separating HIV-gag 
VLPs from EVs (Reiter et al., 2019), and this promising method should be tested for 
extraction of RVFV VLPs. 
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VLP appearance and abundance in samples were examined by immunoelectron 
microscopy, a straightforward and relatively rapid procedure. So far, VLPs have been 
scarce on the grids, often aggregated, and irregularly shaped, all of which makes 
collection of structural data more challenging. Upscaling of VLP expression cultures 
and experimenting with different purification protocols might help to increase VLP 
frequency on the grids. To preserve a symmetrical surface structure for cryo-EM, the 
VLPs could be treated with a fixative agent such as PFA (Halldorsson et al., 2018). 
Unfortunately, no VLPs were observed in the immuno-EM analysis of the PFA-treated 
samples produced in this work, so new PFA-treated VLP samples should be prepared 
and analyzed to test this hypothesis.  
There are alternative approaches to the preparation of cryo-EM grids that might prove 
valuable for developing RVFV VLP sample preparation. Some biomaterials, possibly 
including the VLPs processed in this work, can be corrupted by conventional 
purification methods. Lengthy purification steps may also introduce artifacts and 
favor non-native conformations (Stass et al., 2018). It would therefore be 
advantageous if the VLPs could be attached to the cryo-EM grid directly from the 
biological source, such as cell culture medium, without extra purification steps. 
Antibody-affinity grids have been applied for this purpose: monoclonal antibodies 
targeting the sample are attached to the grid, and the antibody-antigen interaction 
effectively locks the target biocomplex in place for imaging (Yu et al., 2016).  
Sample capture methods relying on antibody-affinity could be further refined by 
taking advantage of covalent interactions. Spy-tag Spy-Catcher technology 
(Reddington & Howarth, 2015) can be used for covalent and irreversible conjugation of 
proteins. By coating the grid with SpyCatcher proteins, the target material could be 
captured by recombinant antibodies equipped with SpyTag. To streamline the process, 
antibodies could even be eliminated from the equation by incorporating the SpyTag 
directly into the target molecules, such as the envelope proteins of RVFV VLPs. There 
is, however, a possibility that the incorporated tag would interfere with the 
ultrastructure of the VLP surface. 
RVFV VLPs have several potential applications in structural research. VLPs can be 
used for studying the glycoprotein shell of RVFV and its interactions with host 
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systems, such as host receptor binding and viral fusion with endosomes. Fusion 
intermediates of RVFV can be studied by modelling endosomes with synthetic 
liposomes, extending the work of Halldorsson et al. (2018). In-cell cryotomography, 
accompanied by focused ion-beam milling to produce electron-permeable sections of 
cells, would be the more ambitious and labor-intensive approach to follow the fusion 
process or VLP formation in its natural context within cells (Pfeffer & Mahamid, 
2018). The exact mechanisms of prospective antivirals could also be examined: several 
antiviral small molecules and peptides show promise for preventing infection by 
blocking RVFV fusion (Atkins & Freiberg, 2017), and understanding their function 
could aid in the intelligent design of new antivirals. 
One important application for the structural characterization of a pathogenic virus is 
examining the neutralizing mechanisms of antibodies raised to combat infection. The 
structures and binding sites of certain antibodies specific to the soluble or adenovirus-
conjugated forms of RVFV Gn and Gc have been analyzed by Hao et al., (2020), Wang 
et al. (2019), and Allen et al. (2018). Wang et al. (2019) noted that they recovered only 
one antibody raised against Gc, which might be due to some Gc-specific antibodies 
targeting conformations other than that of the isolated protein (Wang et al., 2019). 
This highlights the potential of VLPs for representing the native conformation of the 
viral glycoprotein shell when structurally characterizing antibody-antigen complexes. 
New neutralizing antibodies targeting the native conformation of viral glycoproteins 
could also be produced by using VLPs to mimic the native antigenic surface of RVFV. 
RVFV VLPs have been shown to elicit humoral immune responses in animal models 
(Mandell et al., 2010a; Näslund et al., 2009), and antibodies could be isolated from 
animals immunized in this way, without causing RVFV infection.  
Taken together, the results presented here give valuable insight on RVFV virus-like 
particle sample processing for structural analyses. A streamlined protocol for 
processing the VLPs from a plasmid construct to cryo-EM micrographs will greatly 
facilitate research on the structural properties of the RVFV glycoprotein shell. With 
further optimization of the procedures described here, or the application of alternative 
methods, the production of RVFV VLPs has great potential to accelerate structural 
studies of RVFV and development of much-needed therapeutics and vaccines. Applied 
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to other enveloped RNA viruses, similar approaches might have a significant impact 
on the field of structural virology. 
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9  SUPPORTING DATA 
 
 
Figure S1. Density gradient graph plotted from density measurements. Three samples fractionated: a non-
transfected negative control, and transfected samples concentrated by ultrafiltration or PEG dialysis. The density of 
each fraction is plotted in the y-axis and the fraction numbers in the x-axis. The gradients display some 
irregularities but are roughly linear. 
Table S1. Formulation of LB medium. 
10 g Tryptone HISPANLAB H1612  
5 g Yeast extract HISPANLAB H1702 
5 g NaCl  RIEDEL 31434 
  
ad. 1000 ml MilliQ H2O 
 
Table S2. Formulation of LB-agar. 
9 g Tryptone HISPANLAB H1612  
4.5 g Yeast extract HISPANLAB H1702  
13.5 g Agar HISPANLAB H1800 
4.5 g NaCl  RIEDEL 31434 
  
ad. 900 ml MilliQ H2O 
 
Table S3. Formulation of DMEM pH 7,4 (Dulbecco’s modified eagle’s medium). 
135 g Dulbecco’s Modified Eagle’s 
Medium - high glucose 
SIGMA D-7777 (10 l) 
37 g  NaHCO3 (J.T.BAKER 0263) 
Dissolved in 10 L sterile water, pH adjusted to 7.5 with 5 M HCl. 
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Table S4. Formulation of Trypsin-EDTA pH 7,4. 
1,25 g Trypsin 1:250 DIFCO 0152-15 
0,5 g EDTA J.T.BAKER 1073 
20 g    NaCl RIEDEL 31434 
1 g    KCl RIEDEL 31248 
0,875 g NaHCO3 J.T.BAKER 0263 
2,5 g Glucose   ICN 194672 
0,013 g    Phenol red MERCK 7241 
Dissolved in 2500 ml sterile water in total; pH adjusted to 7.4 with 5 M NaOH. 
 
Table S5. Centrifugation parameters for ultrafiltration procedures. 
Filter 
capacity 
Centrifugation 
speed 
Centrifugation 
temperature 
Initial sample 
volume range 
Total centrifugation time for 
concentration 
15 ml 3220 × g +14°C 20-25 ml 30-40 min 
4 ml 3220 × g +14°C 10 ml 35 min 
2 ml 3500 × g ~+20°C 0.1-0.4 ml 30 min 
0.5 ml 14 000 × g ~+20°C 0.1-2 ml 15-30 min 
 
